Clearmind reports investigator update on CMND-100 trial for alcohol use disorder

Clearmind Medicine Inc. said on July 13, 2026 that investigators leading its first-in-human trial of CMND-100 shared updates from a June 10 webinar on the company's MEAI compound, which is being studied for alcohol use disorder.

Dr. Anahita Bassir Nia of Yale School of Medicine and Dr. Jennifer Ellis of Johns Hopkins University said they had a generally favorable view of CMND-100 and the ongoing Phase I/IIa study, and pointed to the substantial unmet need in alcohol use disorder, noting that existing treatment options are few and often carry significant side effects.¹

The investigators outlined several points from the trial so far. They noted that MEAI's non-hallucinogenic profile sets it apart from classical psychedelics, which the investigators said could allow for a simpler and more accessible treatment approach that does not require hospitalization, intensive monitoring, or mandatory psychological or psychiatric supervision.¹ They also said the reduced reliance on subjective psychedelic experiences helps improve blinding and gives a clearer view of the compound's direct pharmacological effects.¹

On enrollment, the update said recruitment has progressed well despite strict eligibility criteria for healthy volunteers.¹ Regarding safety, the investigators described early findings showing no notable adverse effects or cardiac safety issues identified so far.¹

The company said the session also covered study design, dose escalation, pharmacokinetics, and participant experience, and noted potential for MEAI applications beyond alcohol use disorder that would require further research.¹ CEO Adi Zuloff-Shani credited the trial's progress to the research collaboration with the two academic centers.